Discussion
This case report of congenital myasthenia syndrome is unique as no other cases of CMS have been reported so far to have microcephaly.
The girl is 8 years old now, however she was presented with subglottic stenosis at the age of 10 months. Additionally, she was also suffering from severe gastroesophageal reflux, progressive scoliosis, hypotonia, Individuals with COLQ and DOK7 mutations usually do not respond to long-term AChE inhibitor treatment [20] . Some individuals with slow-channel CMS (SCCMS) have been treated with quinidine which can have some major side effects and may be detrimental to individuals with acetylcholine receptor deficiency [21] .
Fluoxetine has been reported to be beneficial for SCCMS [22] , while ephedrine and albuterol have been beneficial to a few individuals, especially those with DOK7 or COLQ mutations [23] . Prophylactic anti-cholinesterase therapy has been recommended to prevent sudden respiratory insufficiency or apneic attacks provoked by fever or infections in those with mutations in ChAT or RAPSN. [9] Parents of an affected infant must be advised to use apnea monitors and should be given basic life support training to counter cardiopulmonary arrest.
It is extremely important to investigate if the disease-causing mutation (mostly autosomal recessive and less commonly autosomal dominant) is also found in asymptomatic family members especially newborns and young children, who could be benefited from early treatment to prevent sudden respiratory failure [8] .
Regarding the distinctiveness of this CMS case with COLQ gene mutation followed by a prescription of oral albuterol with a plan to change to intravenous ephedrine if necessary, the co-occurrence of microcephaly is baffling. This is our main reason for reporting this unique case in the literature with the intention to receive insight and feedback from experts in the field.
Conclusion
This is the first reported case of congenital myasthenia syndrome with microcephaly.
We recommend that care providers should consider microcephaly as one of the clinical presentations for CMS and should start oral albuterol as a trial to roll in with the disease.
